An Introduction to Multiple Myeloma
Despite numerous advances in the last decade, multiple myeloma remains an incurable disease, characterised by relapses that ultimately result in uncontrolled disease and death. However, novel agents, such as proteasome inhibitors, immunomodulatory drugs and CD38-directed monoclonal antibodies, have substantially improved survival and tolerability. These emerging agents include immune checkpoint inhibitors and chimeric antigen receptor-engineered T-cell therapies, although eventual relapse remains an issue.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Our supporting partners do not constitute an endorsement of the content on this page.
Multiple Myeloma Content
CAR T-cell treatment pathway: From patient identification to long-term management
Watch leading experts discuss CAR T-cell treatment pathways in non-Hodgkin lymphoma and multiple myeloma, from patient identification to long-term management.
Oral Therapies for Multiple Myeloma
touchREVIEWS in Oncology & Haematology. 2022;18(2):Online ahead of journal publication
Treatment options for myeloma have rapidly expanded in the past decade and, as with many cancers, the number of oral drug options has increased considerably. Given the more limited number of cancer hospitals, patients often must travel considerable distance to get to their closest cancer centre, which places a significant burden on receiving adequate therapy. […]
Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021
touchREVIEWS in Oncology & Haematology. 2022;18(1):53–8 DOI: https://doi.org/10.17925/OHR.2022.18.1.53
Multiple myeloma (MM) remains largely an incurable disease with only a small percentage of patients achieving long-term remission.1 Here, we highlight some of the major studies on MM presented at the American Society of Hematology meeting in December 2021. Monoclonal gammopathy of undetermined significance and smouldering myeloma The Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) […]
Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient
touchREVIEWS in Oncology & Haematology. 2022;18(1):59–65 DOI: https://doi.org/10.17925/OHR.2022.18.1.59
Background on anti-BCMA CAR-T therapy Despite notable advances in the development of new drugs and the improvement of survival rates over the last 20 years, multiple myeloma (MM) persists as an incurable disease and nearly 35,000 new cases are expected in the USA each year.1,2 The emergence of novel immunotherapies treatments has changed the therapeutic landscape […]
Shaji Kumar, ASH 2021: Final Overall Survival Results from the BELLINI Study
Dr Shaji Kumar, one of our Editors-in-Chief for touchREVIEWS in Oncology & Haematology, discusses his presentation at the 63rd ASH Annual Meeting & Exposition on the final overall survival results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Intro: 00:12-00:18 Questions 1. Could […]
Melphalan Flufenamide: a Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
touchREVIEWS in Oncology & Haematology. 2021;17(2):101–6 DOI: https://doi.org/10.17925/OHR.2021.17.2.101
Multiple myeloma (MM) is the second most common haematological malignancy, affecting an estimated 450,600 patients worldwide, with an estimated 34,920 new diagnoses and 12,410 patient deaths in the USA in 2021.1,2 Although established curative therapies for MM have not yet been defined, we have observed an incremental increase in survival, with a doubling of 5-year survival […]
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
touchREVIEWS in Oncology & Haematology. 2021;17(1):48-54 DOI: https://doi.org/10.17925/OHR.2021.17.1.48
Multiple myeloma is a plasma cell malignancy that typically develops in individuals in their late 60s with an average survival time of ~8 years.1 Despite recent advances in treatment, multiple myeloma remains largely incurable due to development of drug resistance in tumour cells. Patients often relapse even after autologous stem cell transplant and multiple lines […]
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!